Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | TOP2A | P11388 | 5/20 | 0.61 |
| ▸ | TOP2B | Q02880 | 5/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL533283 | 0.88 | NISCH (0.67) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL13327264 | 0.87 | NISCH (0.81) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL6365864 | 0.82 | NISCH (1.00) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL4035056 | 0.78 | NISCH (0.68) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL2513540 | 0.78 | NISCH (0.68) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL4035055 | 0.78 | NISCH (0.68) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL31249900 | 0.78 | NISCH (0.68) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL11462790 | 0.78 | NISCH (1.00) | NISCHGAATSHRTOP2ATOP2B | |
| Hydrochloric Acid SCHEMBL9828172 | 0.77 | NISCH (0.66) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL14029044 | 0.76 | NISCH (0.75) | NISCHGAATSHRTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | NISCH 3757/4885GAA 2639/4885TSHR 987/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | NISCH 3810/4885GAA 2602/4885TSHR 831/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | NISCH 2609/4885GAA 1887/4885TSHR 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.